Ionis reveals no new safety concerns over inotersen, will file imminently in EU & USA

Ionis Pharmaceuticals (Nasdaq: IONS) has presented new data from its Phase III NEURO-TTR study, evaluating inotersen in patients with a hereditary form of the rare disease ATTR amyloidosis.

The results, which are currently being presented at the first European ATTR Amyloidosis meeting in Paris, show significant benefit compared to placebo in both co-primary endpoints, after both eight and 15 months.

The efficacy of inotersen was measured according to a commonly-used quality of life assessment measure, and a disease severity assessment.